Additional Prof., Dept. of Psychiatry, Post Graduate Institute of Medical Education & Research, Chandigarh - 160 012.
Indian J Psychiatry. 2004 Jul;46(3):213-20.
The sexual dysfunctions are one of the most prevalent conditions. Sexual dysfunctions can have profound effect on the psychological well-being of an individual and the psychosexual relationship of a couple. Management of the sexual dysfunction should be preceded by an accurate diagnosis reached after a complete medical and sexual history and physical examination. Current focus of researchers has been on understanding the pathophysiology of erectile dysfunction, premature ejaculation and other sexual dysfunctions that can help in developing newer pharmacological cures for these conditions.Recently, a number of clinical trials have studied the potential effectiveness of the phosphodiesterase (PDE)-5 inhibitor sildenafil in the treatment of Erectile Dysfunction (ED) and Premature Ejaculation (PME). The introduction of PDE-5 inhibitors like sildenafil, vardenafil and tadalafil has revolutionized the treatment of sexual dysfunctions.This review focuses on the recent pharmacological advances in the treatment of common sexual dysfunctions like ED and PME with special focus on the role of PDE-5 inhibitors. Also discussed is the pharmacological treatment of other less prevalent and recognized disorders like female sexual dysfunction, drug induced sexual dysfunction etc.
性功能障碍是最常见的病症之一。性功能障碍会对个人的心理健康和夫妻间的性关系产生深远的影响。在对性功能障碍进行治疗之前,应该通过全面的医学和性史以及身体检查来做出准确的诊断。目前,研究人员的重点是了解勃起功能障碍、早泄和其他性功能障碍的病理生理学,这有助于开发这些病症的新型药物治疗方法。最近,许多临床试验研究了磷酸二酯酶-5(PDE-5)抑制剂西地那非治疗勃起功能障碍(ED)和早泄(PE)的潜在疗效。PDE-5 抑制剂的出现,如西地那非、伐地那非和他达拉非,彻底改变了性功能障碍的治疗方法。这篇综述重点关注了 ED 和 PME 等常见性功能障碍的最新药理学进展,特别关注了 PDE-5 抑制剂的作用。此外,还讨论了其他不太常见和公认的疾病的药物治疗,如女性性功能障碍、药物引起的性功能障碍等。